|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01513 LIVZON PHARMA
Nominal 
21.000 -3.920 (-15.730%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Turnover | 4,999,670 | -20.285% | 6,271,913 | 6,282,354 | 6,689,918 | 6,302,565 |
| Cost of Sales | (1,936,074) | -9.168% | (2,131,486) | -- | -- | -- |
| Gross Profit | 3,063,596 | -26.008% | 4,140,426 | -- | -- | -- |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (10,612) | -57.924% | (25,222) | (50,744) | (85,212) | (119,450) | |
| Profit / (Loss) on Disposal | (523) | 249.407% | (150) | (76) | (328) | (511) | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 47,753 | 64.991% | 28,943 | 13,333 | 37,016 | 37,182 | |
| Profit / (Loss) before Taxation | 1,326,037 | -27.464% | 1,828,110 | 1,608,394 | 1,423,370 | 1,322,573 | |
| Taxation | (205,121) | -25.919% | (276,889) | (253,695) | (249,299) | (205,070) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (188,716) | -30.140% | (270,133) | (183,728) | (39,500) | (99,957) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 932,199 | -27.234% | 1,281,088 | 1,170,971 | 1,134,570 | 1,017,546 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 12,646 | -- | (165,118) | (77,592) | (41,453) | (95,511) |
| Depreciation & Amortisation | 318,139 | 1.520% | 313,375 | 339,809 | 513,207 | 266,864 |
| Directors' Emoluments | 7,522 | 15.658% | 6,503 | 6,519 | 6,213 | 6,228 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| EPS (cts) | 105.000 | -26.573% | 143.000 | 127.000 | 122.000 | 109.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 15.053 | -- | 15.129 | 15.027 | 14.337 | 13.762 |
| Remarks: | Real time quote last updated: 24/08/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 932,199 |
| %Change | -27.234% |
| EPS / (LPS) | RMB 1.050 |
| NBV Per Share (¥) | RMB 15.053 |